THX PharmaFRA:3VG +1.10%30 EBIT per Share is €-0.32 as of Dec. 2025. GuruFocus rates FRA:3VG with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,185 Biotechnology companies, THX Pharma ranks better than 75.7% on this metric.
THX Pharma's EBIT per Share for the
six
months ended in Dec. 2025 was €-0.20.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.32.
During the past 3 years, the average EBIT per Share Growth Rate was 36.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 32.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 9.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for THX Pharma's EBIT per Share or its related term are showing as below:
FRA:3VG'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -50.2 Med: 9.3 Max: 45.5
Current: 36.2
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of THX Pharma was 45.50% per year. The lowest was -50.20% per year. And the median was 9.30% per year.
FRA:3VG's 3-Year EBIT Growth Rate is ranked better than 75.7% of 1185
companies
in the Biotechnology industry
Industry Median: 15.4
vs FRA:3VG: 36.20
THX Pharma's EBIT for the
six
months ended in Dec. 2025 was €-2.80 Mil.
THX Pharma (FRA:3VG) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
THX Pharma EBIT per Share Related Terms
THX Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for THX Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THX Pharma (FRA:3VG) has a EBIT per Share of €-0.32 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #288 out of 1185 companies in the Biotechnology industry, placing it in the top 24.3%.
Is THX Pharma's EBIT per Share too high?
THX Pharma's current EBIT per Share is €-0.32. Based on the distribution chart, THX Pharma ranks #288 out of 1185 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, THX Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #288 out of 1185 companies for EBIT per Share. This places THX Pharma in the top 24% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,185 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on THX Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. THX Pharma's current EBIT per Share is €-0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (FRA:3VG) has a current EBIT per Share of €-0.32. The current EBIT per Share is €-0.32. THX Pharma's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For THX Pharma (FRA:3VG), the current EBIT per Share is €-0.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
30GF Score
Get the complete analysis for FRA:3VG
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3VG has been successfully added to your 
